237 related articles for article (PubMed ID: 29508762)
1. Consensus statement on mandatory measurements in pancreatic cancer trials (COMM-PACT) for systemic treatment of unresectable disease.
Ter Veer E; van Rijssen LB; Besselink MG; Mali RMA; Berlin JD; Boeck S; Bonnetain F; Chau I; Conroy T; Van Cutsem E; Deplanque G; Friess H; Glimelius B; Goldstein D; Herrmann R; Labianca R; Van Laethem JL; Macarulla T; van der Meer JHM; Neoptolemos JP; Okusaka T; O'Reilly EM; Pelzer U; Philip PA; van der Poel MJ; Reni M; Scheithauer W; Siveke JT; Verslype C; Busch OR; Wilmink JW; van Oijen MGH; van Laarhoven HWM
Lancet Oncol; 2018 Mar; 19(3):e151-e160. PubMed ID: 29508762
[TBL] [Abstract][Full Text] [Related]
2. Consensus Statement on Mandatory Measurements for Pancreatic Cancer Trials for Patients With Resectable or Borderline Resectable Disease (COMM-PACT-RB): A Systematic Review and Delphi Consensus Statement.
Pijnappel EN; Suurmeijer JA; Koerkamp BG; Kos M; Siveke JT; Salvia R; Ghaneh P; van Eijck CHJ; van Etten-Jamaludin FS; Abrams R; Brasiuniene B; Büchler MW; Casadei R; van Laethem JL; Berlin J; Boku N; Conroy T; Golcher H; Sinn M; Neoptolemos JP; van Tienhoven G; Besselink MG; Wilmink JW; van Laarhoven HWM
JAMA Oncol; 2022 Jun; 8(6):929-937. PubMed ID: 35446336
[TBL] [Abstract][Full Text] [Related]
3. Radiotherapy technical considerations in the management of locally advanced pancreatic cancer: American-French consensus recommendations.
Huguet F; Goodman KA; Azria D; Racadot S; Abrams RA
Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):1355-64. PubMed ID: 22768988
[TBL] [Abstract][Full Text] [Related]
4. Guidelines for time-to-event end-point definitions in trials for pancreatic cancer. Results of the DATECAN initiative (Definition for the Assessment of Time-to-event End-points in CANcer trials).
Bonnetain F; Bonsing B; Conroy T; Dousseau A; Glimelius B; Haustermans K; Lacaine F; Van Laethem JL; Aparicio T; Aust D; Bassi C; Berger V; Chamorey E; Chibaudel B; Dahan L; De Gramont A; Delpero JR; Dervenis C; Ducreux M; Gal J; Gerber E; Ghaneh P; Hammel P; Hendlisz A; Jooste V; Labianca R; Latouche A; Lutz M; Macarulla T; Malka D; Mauer M; Mitry E; Neoptolemos J; Pessaux P; Sauvanet A; Tabernero J; Taieb J; van Tienhoven G; Gourgou-Bourgade S; Bellera C; Mathoulin-Pélissier S; Collette L
Eur J Cancer; 2014 Nov; 50(17):2983-93. PubMed ID: 25256896
[TBL] [Abstract][Full Text] [Related]
5. Appropriateness of systemic treatments in unresectable metastatic well-differentiated pancreatic neuroendocrine tumors.
Strosberg JR; Fisher GA; Benson AB; Anthony LB; Arslan B; Gibbs JF; Greeno E; Iyer RV; Kim MK; Maples WJ; Philip PA; Wolin EM; Cherepanov D; Broder MS
World J Gastroenterol; 2015 Feb; 21(8):2450-9. PubMed ID: 25741154
[TBL] [Abstract][Full Text] [Related]
6. Essential variables for reporting research studies on fetal growth restriction: a Delphi consensus.
Khalil A; Gordijn SJ; Beune IM; Wynia K; Ganzevoort W; Figueras F; Kingdom J; Marlow N; Papageorghiou AT; Sebire N; Zeitlin J; Baschat AA
Ultrasound Obstet Gynecol; 2019 May; 53(5):609-614. PubMed ID: 30125411
[TBL] [Abstract][Full Text] [Related]
7. Reporting of patient characteristics and stratification factors in phase 3 trials investigating first-line systemic treatment of metastatic colorectal cancer: A systematic review.
Goey KKH; Mahmoud R; Sørbye H; Glimelius B; Köhne CH; Sargent DJ; Punt CJA; van Oijen MGH; Koopman M
Eur J Cancer; 2018 Jun; 96():115-124. PubMed ID: 29729562
[TBL] [Abstract][Full Text] [Related]
8. Locally Advanced, Unresectable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline.
Balaban EP; Mangu PB; Khorana AA; Shah MA; Mukherjee S; Crane CH; Javle MM; Eads JR; Allen P; Ko AH; Engebretson A; Herman JM; Strickler JH; Benson AB; Urba S; Yee NS
J Clin Oncol; 2016 Aug; 34(22):2654-68. PubMed ID: 27247216
[TBL] [Abstract][Full Text] [Related]
9. Selecting Core Outcomes for Randomised Effectiveness trials In Type 2 Diabetes (SCORE-IT): study protocol for the development of a core outcome set.
Harman NL; Wilding J; Curry D; Harris J; Logue J; Pemberton RJ; Perreault L; Thompson G; Tunis S; Williamson PR;
Trials; 2018 Aug; 19(1):427. PubMed ID: 30086771
[TBL] [Abstract][Full Text] [Related]
10. No standard treatment is available for advanced pancreatic cancer.
Lionetto R; Pugliese V; Bruzzi P; Rosso R
Eur J Cancer; 1995 Jun; 31A(6):882-7. PubMed ID: 7646915
[TBL] [Abstract][Full Text] [Related]
11. Reporting quality of abstracts in phase III clinical trials of systemic therapy in metastatic solid malignancies.
Sivendran S; Newport K; Horst M; Albert A; Galsky MD
Trials; 2015 Aug; 16():341. PubMed ID: 26253548
[TBL] [Abstract][Full Text] [Related]
12. The quality of randomised controlled trials may be better than assumed.
del Giglio A; Costa LJ
BMJ; 2004 Jan; 328(7430):24-5. PubMed ID: 14703541
[No Abstract] [Full Text] [Related]
13. Prognostic factors and sites of metastasis in unresectable locally advanced pancreatic cancer.
Peixoto RD; Speers C; McGahan CE; Renouf DJ; Schaeffer DF; Kennecke HF
Cancer Med; 2015 Aug; 4(8):1171-7. PubMed ID: 25891650
[TBL] [Abstract][Full Text] [Related]
14. Development of a core outcome set for clinical trials in squamous cell carcinoma: study protocol for a systematic review of the literature and identification of a core outcome set using a Delphi survey.
Schlessinger DI; Iyengar S; Yanes AF; Chiren SG; Godinez-Puig V; Chen BR; Kurta AO; Schmitt J; Deckert S; Furlan KC; Poon E; Cartee TV; Maher IA; Alam M; Sobanko JF
Trials; 2017 Jul; 18(1):321. PubMed ID: 28701207
[TBL] [Abstract][Full Text] [Related]
15. Validation of the Royal Marsden Hospital prognostic score in patients treated in the Phase I Clinical Trials Program at the MD Anderson Cancer Center.
Garrido-Laguna I; Janku F; Vaklavas C; Falchook GS; Fu S; Hong DS; Naing A; Tsimberidou AM; Wen S; Kurzrock R
Cancer; 2012 Mar; 118(5):1422-8. PubMed ID: 21823111
[TBL] [Abstract][Full Text] [Related]
16. A reporting guideline for clinical platelet transfusion studies from the BEST Collaborative.
Meyer E; Delaney M; Lin Y; Morris A; Pavenski K; Tinmouth A; Murphy M; Slichter SJ; Heddle N; Dumont LJ
Transfusion; 2013 Jun; 53(6):1328-34. PubMed ID: 23003345
[TBL] [Abstract][Full Text] [Related]
17. Reporting data on homeopathic treatments (RedHot): a supplement to CONSORT.
Dean ME; Coulter MK; Fisher P; Jobst K; Walach H
Homeopathy; 2007 Jan; 96(1):42-5. PubMed ID: 17227747
[TBL] [Abstract][Full Text] [Related]
18. Developing a core set of patient-reported outcomes in pancreatic cancer: A Delphi survey.
Gerritsen A; Jacobs M; Henselmans I; van Hattum J; Efficace F; Creemers GJ; de Hingh IH; Koopman M; Molenaar IQ; Wilmink HW; Busch OR; Besselink MG; van Laarhoven HW;
Eur J Cancer; 2016 Apr; 57():68-77. PubMed ID: 26886181
[TBL] [Abstract][Full Text] [Related]
19. Reporting data on homeopathic treatments (RedHot): a supplement to CONSORT.
Dean ME; Coulter MK; Fisher P; Jobst KA; Walach H
J Altern Complement Med; 2007; 13(1):19-23. PubMed ID: 17309373
[TBL] [Abstract][Full Text] [Related]
20. Deficiencies in health-related quality-of-life assessment and reporting: a systematic review of oncology randomized phase III trials published between 2012 and 2016.
Marandino L; La Salvia A; Sonetto C; De Luca E; Pignataro D; Zichi C; Di Stefano RF; Ghisoni E; Lombardi P; Mariniello A; Reale ML; Trevisi E; Leone G; Muratori L; Marcato M; Bironzo P; Novello S; Aglietta M; Scagliotti GV; Perrone F; Di Maio M
Ann Oncol; 2018 Dec; 29(12):2288-2295. PubMed ID: 30304498
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
